Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title Sort descending | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required) | PAR-24-172 | NHLBI | The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders… More | ||
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required) | PAR-24-173 | NHLBI | The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders… More | ||
| NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) | RFA-HL-26-003 | NHLBI | The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program… More | ||
| NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) | RFA-HL-26-002 | NHLBI | The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program… More | ||
| NHLBI Program Project Applications (P01 Clinical Trials Optional) | PAR-24-065 | NHLBI | The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and… More | ||
| NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed) | PAR-22-194 | NHLBI | This Funding Opportunity Announcement (FOA) invites applications to use the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-… More | ||
| NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed) | PAR-21-220 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).… More | ||
| NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed) | PAR-24-120 | NIA | The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored researchers to tenure-track faculty conducting research that advances the mission of NIA. This three-… More | ||
| NIA MSTEM: Advancing Diversity in Aging Research (ADAR) through Undergraduate Education (R25 - Independent Clinical Trial Not Allowed) | PAR-24-135 | NIA | ThisNotice of Funding Opportunity (NOFO) invites R25 applications to support the development and implementation of research education programs forundergraduate students from diverse backgrounds,… More | ||
| NIA Postdoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F32 Clinical Trial Not Allowed) | PAR-21-217 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).… More |